Coming Soon – September 2019
Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is a severely undertreated disease. The failure of therapies in the past to improve walking distance or reduce amputation highlights the high need for novel agents capable of reducing, preventing, or reversing the progression of PAD. We discuss how current therapies are differentiated based on performance of key drug attributes and measure the impact of these attributes on physicians’ prescribing behavior. We also discuss the most important unmet needs in the treatment of PAD and consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the key trade-offs that surveyed physicians are willing to make for these attributes when considering new treatment options for PAD.
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- Which PAD therapies are perceived by U.S. and European physicians as performing best on key treatment drivers and goals?
- What are the major areas of opportunity for drug developers in PAD treatment and their likelihood of being fulfilled in the near future?
- Based on the conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and price are acceptable to U.S. and European physicians for a hypothetical new PAD drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European cardiologists
Key Drugs Covered: Aspirin, clopidogrel, statins, ACE/ARBs, Xarelto, Repatha, vasoactive agents
Key Metrics Included Target Product Profile (TPP) simulator based on conjoint analysis methodology. Stated vs. derived importance of product attributes on prescribing behavior. Assessment of current drug performance against treatment drivers and goals. Physician perceptions of unmet needs in the indication and related indications. Analysis of remaining drug development opportunities.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
- Detailed, Expanded Analysis (US & EU)
- Coming Soon
- Coming Soon
- Coming Soon
Author(s): Pallavi Malik, M.Sc
Pallavi Malik is a business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Biotechnology, and a Bachelor's degree in Science from the Panjab University, Chandigarh, India. Prior to joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve. Her role involved in-depth scientific secondary research, and competitive intelligence across multiple domains (such as oncology, ophthalmology and CVD) including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, competitor benchmarking, and opportunity assessment.